Clinical trial
A Multi-center, Prospective, Non-randomized, Open-label Study of the Efficacy and Safety of Osimertinib Combined With Aspirin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Are T790M-positive and Resistant to First-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
NCT03543683 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Prospective, Non-randomized, Open-label Study of the Efficacy and Safety of Osimertinib Combined With Aspirin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Are T790M-positive and Resistant to First-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 1, 2018
- Completion date
- June 1, 2024
- Enrollment
- 115 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
egfr t790m, non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv